| Name | Title | Contact Details |
|---|
Reichert Analytical Instruments is a Depew, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Precision BioSciences is a publicly held biotechnology company dedicated to improving life through its next generation gene editing technology, ARCUS. Precision`s cell therapy, gene therapy, and agriculture programs are based on the proprietary ARCUS gene editing platform, which features coordinated target site binding and DNA cutting to ensure precise edits. Our team includes pioneers in genome engineering, biotech business leaders, and a growing staff of committed Precisioneers. We work together in our beautifully designed, award-winning space in vibrant downtown Durham, NC; a place with great restaurants and museums as well as fantastic housing and schools. Precision provides all employees a sense of purpose, thoughtfully designed laboratory and office spaces, and opportunities to train and grow – not to mention plentifully stocked kitchens and fantastic benefits. At Precision BioSciences, we are excited to work together toward improving lives by realizing the potential of gene editing.
Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system`s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.
LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic and acquired diseases.
GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company`s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.